Business Description
Genelux Corp
NAICS : 541714
SIC : 2834
ISIN : US36870H1032
Description
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 8.28 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.16 | |||||
Debt-to-EBITDA | -0.1 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -11.67 | |||||
Beneish M-Score | -377.64 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -29.6 | |||||
3-Year EPS without NRI Growth Rate | -25.6 | |||||
3-Year FCF Growth Rate | -41.8 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 19.52 | |||||
9-Day RSI | 32.86 | |||||
14-Day RSI | 37.68 | |||||
6-1 Month Momentum % | -79.07 | |||||
12-1 Month Momentum % | -90.75 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.72 | |||||
Quick Ratio | 2.72 | |||||
Cash Ratio | 2.51 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.2 | |||||
Shareholder Yield % | -10.76 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -322725 | |||||
Net Margin % | -322287.5 | |||||
FCF Margin % | -262312.5 | |||||
ROE % | -154.33 | |||||
ROA % | -97.21 | |||||
ROIC % | -503.94 | |||||
ROC (Joel Greenblatt) % | -867.98 | |||||
ROCE % | -141.37 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 348.17 | |||||
PB Ratio | 3.91 | |||||
Price-to-Tangible-Book | 3.91 | |||||
EV-to-EBIT | -1.89 | |||||
EV-to-Forward-EBIT | -1.97 | |||||
EV-to-EBITDA | -1.97 | |||||
EV-to-Revenue | 6087.5 | |||||
EV-to-Forward-Revenue | 6087.47 | |||||
EV-to-FCF | -2.32 | |||||
Price-to-Net-Current-Asset-Value | 5.09 | |||||
Price-to-Net-Cash | 5.92 | |||||
Earnings Yield (Greenblatt) % | -52.91 | |||||
FCF Yield % | -27.89 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GNLX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genelux Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.008 | ||
EPS (TTM) ($) | -0.97 | ||
Beta | 0 | ||
Volatility % | 74.25 | ||
14-Day RSI | 37.68 | ||
14-Day ATR ($) | 0.253828 | ||
20-Day SMA ($) | 2.183 | ||
12-1 Month Momentum % | -90.75 | ||
52-Week Range ($) | 1.71 - 30.44 | ||
Shares Outstanding (Mil) | 34.35 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Genelux Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Genelux Corp Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Genelux Corp Frequently Asked Questions
What is Genelux Corp(GNLX)'s stock price today?
The current price of GNLX is $2.19. The 52 week high of GNLX is $30.44 and 52 week low is $1.71.
When is next earnings date of Genelux Corp(GNLX)?
The next earnings date of Genelux Corp(GNLX) is 2024-08-14 Est..
Does Genelux Corp(GNLX) pay dividends? If so, how much?
Genelux Corp(GNLX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |